GSK3915393

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Idiopathic Pulmonary Fibrosis

Phase 1

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

CompletedNCT06625489

GlaxoSmithKlineIdiopathic Pulmonary Fibrosis

Start: 2024-10-07End: 2024-11-25Updated: 2025-02-18

Phase 2

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

TerminatedNCT06317285

GlaxoSmithKlineIdiopathic Pulmonary Fibrosis

Start: 2024-04-04End: 2025-10-01Updated: 2026-09-18